Pay in 4 interest-free payments of $20.00 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
The comparable efficacy is observed at relatively low doses (10 mg/kg per day)
R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies
09 mM) Ethanol 48 mg/mL (198
20-heptaoxadocosan-22-yloxy)-4-(prop-2-en-1-yl)-12-oxa-4-azapentacyclo[9
Smiles: CC1C=C(NN=1)NC1C=C(CN2CCOCC2)C2=NC(C)=C(CC3=CC=C(Cl)C=C3F)N2N=1
Vandetanib - CAS# 443913-73-3 CRABP-II Degrader-1 The comparable efficacy is observedVandetanib is an orally bioavailable 4 anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGF2), thereby blocking VEGF stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell